Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Esperante Ventures

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 20
Average round size
info
The average size of a deal this fund participated in
$3M
Portfolio companies 15
Rounds per year 1.00
Lead investments 3
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.25
Exits 3
Key employees 1
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Pharmaceutical
  • Therapeutics
Summary

Esperante Ventures appeared to be the VC, which was created in 2004. The main department of described VC is located in the Hoofddorp. The company was established in Europe in The Netherlands.

Opposing the other organizations, this Esperante Ventures works on 8 percentage points less the average amount of lead investments. The fund is constantly included in less than 2 investment rounds annually. The important activity for fund was in 2011. Despite it in 2019 the fund had an activity. Considering the real fund results, this VC is 13 percentage points less often commits exit comparing to other organizations. The common things for fund are deals in the range of 1 - 5 millions dollars. The increased amount of exits for fund were in 2016.

Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Biotechnology, Medical Device. The fund has exact preference in some founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United Kingdom. Among the various public portfolio startups of the fund, we may underline Anergis, Atox Bio, Haemostatix

We also calculated 1 valuable employee in our database.

The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Esperante Ventures, startups are often financed by Spark Ventures, Northstar Ventures, Nesta Ventures. The meaningful sponsors for the fund in investment in the same round are Northstar Ventures, Longwall Venture Partners, Wellcome Trust. In the next rounds fund is usually obtained by Wellcome Trust, Sunstone Life Science Ventures, Renaissance PME Foundation.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Esperante Ventures:
Typical Co-investors
Esperante Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Esperante Ventures:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from The Netherlands
Funds with similar focus located in The Netherlands:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Versantis

Health Care
Health Diagnostics
Pharmaceutical
Therapeutics
$17M18 Sep 2019 Zürich, Zurich, Switzerland

Biotechnology
Health Care
Health Diagnostics
Medical Device
$2M03 Oct 2017 England

Biotechnology
Health Care
Health Diagnostics
Medical Device
$588K14 Feb 2014 England

Cytox

Biotechnology
Genetics
$4M30 Jan 2013 England

Biotechnology
Health Care
Health Diagnostics
Medical Device
$875K31 Aug 2012 England

Atox Bio

Biotechnology
Clinical Trials
Therapeutics
$3M19 Dec 2011 North District

Haemostatix

Biotechnology
Clinical Trials
Health Care
Medical
01 Aug 2011 Nottingham, England, United Kingdom

Anergis

Biotechnology
Health Care
Life Science
Medical
Personal Health
$20M28 Mar 2011 Vaud, Switzerland

Karus Therapeutics

Biotechnology
Life Science
Pharmaceutical
$959K04 May 2010 Test Valley, England, United Kingdom

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Esperante Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 20
Average round size 3M
Rounds per year 1.00
Peak activity year 2011
Lead investments 3
Follow on index 0.25
Exits 3
Group Appearance index 0.90

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Versantis

Health Care
Health Diagnostics
Pharmaceutical
Therapeutics
$17M18 Sep 2019 Zürich, Zurich, Switzerland

Biotechnology
Health Care
Health Diagnostics
Medical Device
$2M03 Oct 2017 England

Biotechnology
Health Care
Health Diagnostics
Medical Device
$588K14 Feb 2014 England

Cytox

Biotechnology
Genetics
$4M30 Jan 2013 England

Biotechnology
Health Care
Health Diagnostics
Medical Device
$875K31 Aug 2012 England

Atox Bio

Biotechnology
Clinical Trials
Therapeutics
$3M19 Dec 2011 North District

Haemostatix

Biotechnology
Clinical Trials
Health Care
Medical
01 Aug 2011 Nottingham, England, United Kingdom

Anergis

Biotechnology
Health Care
Life Science
Medical
Personal Health
$20M28 Mar 2011 Vaud, Switzerland

Karus Therapeutics

Biotechnology
Life Science
Pharmaceutical
$959K04 May 2010 Test Valley, England, United Kingdom
Crunchbase icon

Content report

The following text will be sent to our editors: